Platelet-derived microparticles, activated platelets, and monocyte-derived microparticles were measured in 73 patients with diabetes mellitus. A comparative study of these parameters was performed before and after administration of ticlopidine. The number of platelet-derived microparticles and activated platelets was increased significantly in diabetic patients. Monocyte-derived microparticles were also increased significantly. After administration of ticlopidine, platelet-derived microparticles and activated platelets corrected positively, not only CD62P-and CD63-positive platelets, but also platelet-derived microparticles and monocyte-derived microparticles showed a significant decrease. These data suggest that in patients with diabetes, platelet-derived microparticles and activated platelets stimulate the activation of monocytes and promote the production of monocyte-derived microparticles, and that ticlopidine is useful for hypercoagulabillity in diabetic patients.
Increased platelet adhesion and aggregation has been reported in patients with diabetes mellitus (1, 2) . Atherosclerosis occurs in this disease (2, 3) and also is the major cause of death in patients with diabetes mellitus, leading to a high mortality in all forms of the disease (4) . Plateletderived microparticles (PDMPs) are produced by either platelet activation or physical stimulation under various conditions (5) (6) (7) (8) . PDMPs contain inner granules, membranous fragments produced by mechanical destruction (5) , and have a coagulative activity (6) .
Monocytes and macrophages may play important roles in the development of atherosclerosis (9) (10) (11) (12) . Monocytes can synthesize procoagulants, and this ability has been confined largely to tissue factors (13, 14) . Monocyte vesiculation has been presented as a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide (15) . This ability of endotoxin-stimulated monocytes to release heterogenous monocyte-derived microparticles (MDMPs) has been postulated to be a mechanism for regulating vascular cell effector functions (16) . MDMPs promote prothrombinase complex assembly, thus facilitating intravascular generation of thrombin and enhanced procoagulant activity (17) .
Monocytes and platelets are very important for vascular events in diabetes mellitus, but no in vivo findings exist concerning MDMP levels in diabetes patients. In this study, we measured and compared the levels of plasma MDMPs, PDMPs, and the surface proteins GMP-140(CD62P) and GP-53(CD63) on activated platelets in patients with diabetes and in normal controls to develop a better understanding of their potential contribution to diabetic vascular complications. Moreover, we have evaluated the effect of ticlopidine on the above-mentioned parameters.
MATERIALS AND METHODS

Patients
The subjects of this study were 50 healthy volunteers and 73 type 2 diabetic patients. Table 1 shows the characteristics of patients and control subjects. Diabetic complications included symptomatic neuropathy treated medically (23 cases, 32%), retinopathy (34 cases, 47%), and nephropathy (29 cases, 40%). Serum creatinine was less than 2.0 mg/dL in all patients. In addition, we orally administered ticlopidine of 200 mg/day for 1 month to 21 patients with diabetes, and compared PDMP, activated platelets, and MDMP levels before and 1 month after administration. All gave informed consent according to the Declaration of Helsinki.
Methods
Flow Cytometry of Activated Platelets and Microparticles
Blood sample were collected into tubes containing 3.8% sodium citrate (9:1 vol/vol). Platelet-rich plasma (PRP) was prepared by centrifugation at 200 g for 10 minutes at room temperature. Washed platelets were prepared by centrifuging PRP at 1400 g for 10 minutes at room temperature. The resultant pellet was washed twice with washing buffer (9 mmol/L Na 2 EDTA, 14.0 mmol/L NaCl, and 26 mmol/L Na 2 HPO 4 , pH 7.2) and resuspended in Hepes-Throde's buffer (129 mmol/L NaCl, 8.9 mmol/L NaHCO 3 , 0.8 mmol/L KH 2 PO 4 , 0.8 mmol/L MgCl 2 , 5.6 mmol/L glucose, and 10 mmol/L Hepes, pH 7.4). An equal volume of 2% paraformaldehyde was added to the washed platelets, and they were incubated for 15 minutes at room temperature. Platelets were then washed twice, resuspended in stock solution (9 mmol/L Na 2 EDTA, 26.4 mmol/L Na 2 HPO 4 2H 2 O, 140 mmol/L NaCl, 0.1% NaN 3 , and fetal bovine serum, pH 7.2), and stored at 4°C until analysis.
PDMP were detected with a modified version of a previously reported method (8, 18, 19) . Ten microliters of platelet suspension (3 × 10 8 /mL) was added to 100 µL of Hepes-Tyrode's buffer containing 5 nmol/L EGTA, and 1000 g for 15 minutes to yield a supernatant containing microparticles only. Ten microliters of washed intact platelets (3 × 10 8 /mL) was then added to the supernatant, and incubation with KMP-9 (20) , (a FITC-labeled monoclonal antibody, against platelet GPIX) was performed for 30 minutes in the dark at room temperature. After incubation, samples were diluted 1:10 with Hepes-Tyrode's buffer containing 5 nmol/L EGTA and analyzed with an Ortho Cytoron Absolute Analyzer (Ortho Diagnostic Systems, Tokyo, Japan). Only cells and particles positive for GPIX were gated in order to distinguish platelets and PDMPs from electronic noise. To differentiate between platelets and PDMPs, the lower limit of the platelet gate was set at the left limit of the forward-scatter profile of resting platelets. Ten thousand FITC-positive particles in the PDMP gate were then counted to determine the number of PDMPs released per 10,000 platelets. As an index of platelet activation, CD62P expression was quantified by immunostaining with anti-CD62P monoclonal antibody (CLB-thromb/6, Immunotech, Marseille, France). 
Assessment of MDMP
MDMP was detected by a previously reported but slightly modified method (16) . Ten microliters of washed intact platelets (3 × 10 8 /mL) was added to the plasma, and the mixture was incubated with FITC-labeled Annexin V (FITC-Ann V) and phycoerythrin (PE)-labeled CD14(PE-CD14) for 30 minutes in the dark at room temperature. Samples were diluted 1:10 with Hepes-Tyrode's buffer containing 5 nmol/L EGTA and analyzed with an Ortho Cytoron Absolute Analyzer (Ortho Diagnostics). Flow cytometry was set to detect only particles bound to FITC-Ann V and PE-CD14 ( Fig. 1) .
Statistics
Statistical analysis was performed using paired or unpaired t-test, p values less than 0.05 being considered statistically significant.
RESULTS
Plasma PDMP levels were significantly higher (p<0.001) in the diabetes group (585±25/10 4 platelet, mean±SE) than in the control group (263±9/10 4 platelets). The number of CD62Ppositive platelets was significantly higher in the diabetic group (28.1±1.4%) than in the control group (9.4±0.6%) The mean number of CD63positive platelets was also significantly higher (p<0.001) in the diabetic group (28.1±1.4%) than in the control group (8.6±0.5%) ( Table 2 ). Fig. 2 shows the results of MDMPs in normal subjects and type 2 diabetic patients. Type 2 diabetic patients (88±6.0/10 4 platelet) showed higher value than in normal subjects (53±3.0/10 4 platelet). Fig. 3 shows the correlation between MDMPs and platelet activation markers (CD62P, CD63, and PDMPs). MDMPs correlated positively with these platelet activation markers (p<0.001), particularly the relation with PDMPs being highly significant. However, HbA1c, an indicator of glycemic control, did not show a significant correlation between MDMPs, PDMPs, CD62P, and CD63.
In the examination of the diabetic complications, MDMPs were assessed according to the complication of nephropathy, retinopathy, or neuropathy. The diabetic patients with complications showed significantly higher MDMP levels that those without complications. The elevation of MDMPs was most significant in patients with nephropathy. Table 3 lists PDMPs, activated platelets, and MDMPs values before and after treatment with ticlopidine. Platelet-derived microparticles, CD62P, CD63, and monocyte-derived microprticles were significantly reduced (PDMPs: from 734±28 to 539±33/10 4 platelet [p<0.001], CD62P: from 33±2.6 to 18±1.5% [p<0.001], CD63: from 33±2.7 to 22±1.4% [p<0.001], and MDMPs: from 110±11 to 87±7.5/10 4 platelet [p<0.001]). The mean levels of all parameters were significantly reduced by the ticlopidine treatment. 
DISCUSSION
The present study shows that levels of PDMPs, activated platelets (CD62P-and CD63-positive platelets), and MDMPs are elevated with diabetes and that these elevation are detected significantly in diabetes complicated with nephropathy. Moreover, MDMPs correlated positively with PDMPs and activated platelets. After administration of ticlopidine, not only activated platelets, but also PDMPs and MDMPs, were significantly decreased.
PDMPs play an important role in the coagulation process. Sims and colleagues (6,21) formed many factor V biding sites in PDMPs activated by C5b-9 and thrombin. They also showed that PDMPs play a major role in production of thrombin by factor Va-Xa complex and that PDMPs are a major factor responsible for the procoagulant activity of platelets. Therefore, elevated levels of PDMPs suggest hypercoagulability (22) . Increased PDMPs are not a finding specific to diabetes mellitus; PDMPs are also increased in uremia or cerebral infarction, which are also dis-eases in which activated platelet are detected in vivo (23, 24) . Enhanced platelet aggregation and adhesion have been described in diabetes mellitus (25) . In addition, there are some reports showing that activated platelets and PDMPs were elevated in type 2 diabetes (8, (26) (27) (28) (29) . In the previous study, we found that the levels of MDMPs in type 2 diabetic patients are higher than those in controls (30) . Mesri and colleagues (16) reported that co-culturing leukocytes with endothelium induces endothelial activation and inflammatory gene induction, and that this pathway is medicated by membrane microparticles released from the activated leukocytes. Our findings suggest that PDMPs and MDMPs participate in the development of atheroscrelosis in patients with type 2 diabetes. The activation of monocytes seems to be enhanced because the level of MDMPs is elevated in type 2 diabetic patients. In addition, levels of soluble E-selectin also increase significantly in type 2 diabetic patients with nephropathy (30) . In general, a subset of monocytes and lymphocytes interact and activate endothelial cells. Increased expression of endothelial adhesion molecules may accelerate vascular damage (29) , and it is possible that they are stimulated by oxidized low-density lipoprotein. Increased activated platelets and PDMPs, which lead to infiltration of monocytes into the arterial wall, have been suggested to be crucial in the development of atherosclerosis (31) .
We studied the effect of an antiplatelet drug, ticlopidine, in the 21 patients with diabetes. CD62P-and CD63-positive platelets were significantly decreased after the administration of ticlopidine, confirming the antiplatelet effect of the drug. Moreover, not only PDMPs, but also MDMPs were significantly reduced after administration of ticlopidine. Therefore, the PDMPs and activated platelets seem to stimulate the activation of monocytes and to promote the production of MDMPs, because both MDMPs and PDMPs showed a positive correlation with activated platelets and decreased after administration of ticlopidine. In addition, treatment with ticlopidine is a useful anticoagulation therapy because it suppresses production of intrinsic coagulant released when platelets are activated.
In conclusion, the levels of MDMPs and platelet activation markers are significantly higher in patients with diabetes than controls. Levels of activated platelets, PDMPs, and MDMPs decreased after treatment with ticlopizine. These data suggest that in patients with diabetes, PDMPs and activated platelets stimulate the activation of monocytes and promote the production of MDMPs, and that ticlopidine is useful in the state of hypercoagulability in diabetic patient.
